Study Compares Xolair to Oral Immunotherapy in Treating Food Allergies
Xolair was superior to oral immunotherapy in both effectiveness and fewer side effects for people with one or more food allergies.
Tag: Genetech
All
Latest
Study Compares Xolair to Oral Immunotherapy in Treating Food Allergies
Xolair was superior to oral immunotherapy in both effectiveness and fewer side effects for people with one or more food allergies.
Read MoreFDA Approves Tecentriq for Early NSC Lung Cancer
The FDA has approved atezolizumab (brand name Tecentriq, Genetech)Â as adjuvant treatment following surgery and platinum-based chemotherapy for adults with Stage II-IIIAÂ non-small cell lung cancer.
Read More
FDA Authorizes Monoclonal Antibody Actemra for Hospitalized COVID-19 Patients
The US FDA issued an emergency use authorization for the monoclonal antibody Actemra (tocilizumab) for the treatment of hospitalized adults and pediatric patients age 2 and older.
Read More
Xolair Prefilled Syringe Approved for self-administration
The US FDA has approved Genetech’s Xolair (omalizumab) prefilled syringe for self-injection for the treatment of moderate to severe persistent allergic asthma, chronic idiopathic urticaria, and nasal polyps.
Read More
FDA Approves Xolair for Nasal Polyps
Xolair is now FDA-approved across three diseases, including persistent allergic asthma, chronic idiopathic urticaria, and now nasal polyps.
Read More
FDA Expands Xofluza Approval Approval for Post-exposure Prevention
The FDA expanded the approved indication for Genetech’s Xofluza (baloxavir marboxil) to include post-exposure prevention of influenza for patients 12 years of age and older after contact with an individual who has the flu.
Read More
Xolair One Step Closer to Self-administration Approval
The FDA accepted a sBLA for a new self-administration option for Xolair (omalizumab) across all approved US indications, according to Genetech.
Read More
FDA Accepts Xolair sBLA for Treatment of Nasal Polyps
Xolair would become the first antibody to help reduce the size of nasal polyps and help improve symptoms through blocking immunoglobulin E.
Read MoreTecentriq Approved for Metastic Non-squamous NSCLC
Tecentriq plus chemotherapy combination demonstrated a significant overall survival and progression-free survival benefit.
Read More
FDA Approves Xolair for Allergic Asthma in Children 6-11
Genentech announced that the FDA has approved Xolair to treat moderate to severe persistent asthma in specific children 6 to 11 years of age.
Read More
Xolair Highly Effective for Severe Allergic Asthma
Xolair (omalizumab) was “highly effective” for the management of severe allergic asthma, according to research published in Allergy and reported by HealthDay News.
Read More
FDA Adds Black Box to Genentech Asthma Drug Xolair
U.S. regulators on Monday finalized a strong new label warning patients and doctors about a potentially severe allergic reaction to Genentech Inc.’s asthma drug Xolair (omalizumab).
Read More